Neoadjuvant endocrine treatment of women with breast cancer


Neoadjuvant therapy has four goals in breast cancer: decrease tumor volume to operate tumors that initially were inoperable, increase the number of conservative surgeries, evaluate the chemosensitivity in vivo and analyze the management of micrometastases. Neoadjuvant treatment provides a unique setting in which we can monitor clinical, pathological, proliferative and molecular responses. Combining different strategies such us surgery, radiation therapy, chemotherapy, and endocrine therapy has contributed substantially to the survival improvement in breast cancer. Third-generation aromatase inhibitors have proven to be superior to tamoxifen in the adjuvant and, more recently, the neoadjuvant treatment of postmenopausal patients. The need to define how to select the patients that will benefit the most from these therapies, the optimal duration of treatment, the best method to evaluate the treatment response, the identification of predictive factors for response, and the superiority of certain endocrine agents over others have been reviewed. We have carried out a critical analysis of the current literature on the utilization of endocrine therapy in the neoadjuvant setting for breast cancer. This review discusses the current evidence regarding primary endocrine therapy and the current opinions on length of treatment and measurement of response prior to surgery.

This is a preview of subscription content, access via your institution.


  1. 1.

    Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer 103:759–764

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Liu SV, Melstrom L, Yao K et al (2010) Neoadjuvant therapy for breast cancer. J Surg Oncol 101:283–291

    PubMed  Article  CAS  Google Scholar 

  3. 3.

    Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233–1241

    PubMed  Article  Google Scholar 

  4. 4.

    Colleoni M, Gelber S, Coates AS et al (2001) Influence of endocrine-related factors on response to perioperative chemotherapy for pts with node-negative breast cancer. J Clin Oncol 19:4141–4149

    PubMed  CAS  Google Scholar 

  5. 5.

    Gianni L, Baselga J, Eiermann W et al (2002) First report of the European Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease. Proc Am Soc Clin Oncol 21:Abstract 132

  6. 6.

    Gianni L, Baselga J, Eiermann W et al (2005) Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11:8715–8721

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949

    PubMed  Article  Google Scholar 

  8. 8.

    Mauriac L, MacGrogan G, Avril A et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47–52

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment, with illustrative cases. Lancet 2:104–107

    Article  Google Scholar 

  10. 10.

    Kiang DT, Kennedy BJ (1977) Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med 87:687–690

    PubMed  CAS  Google Scholar 

  11. 11.

    Legha SS, Buzdar AU, Hortobagyi GN et al (1979) Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA 242:49–52

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Early Breast Cancer Trialists Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  13. 13.

    Paridaens R, Therasse P, Dirix L et al (2002) First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal pts (pts)—a randomized phase III trial of the EORTC breast group. Proc Am Soc Clin Oncol 22:abstract 515

    Google Scholar 

  14. 14.

    Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391–1398

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Bonneterre J, Thürlimann B, Robertson JF et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748–3757

    PubMed  CAS  Google Scholar 

  16. 16.

    Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758–3767

    PubMed  CAS  Google Scholar 

  17. 17.

    Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606

    PubMed  CAS  Google Scholar 

  18. 18.

    Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462

    PubMed  Article  CAS  Google Scholar 

  20. 20.

    Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17:vii10–vii14

    Google Scholar 

  21. 21.

    Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492

    PubMed  Article  CAS  Google Scholar 

  22. 22.

    Baum M, Buzdar A, Cuzick J, Forbes J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Preece PE, Wood RA, Mackie CR et al (1982) Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study. Br Med J 284:869–870

    Article  CAS  Google Scholar 

  24. 24.

    Helleberg A, Lundgren B, Norin T et al (1982) Treatment of early localized breast cancer in elderly pts by tamoxifen. Br J Radiol 55:511–515

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Bradbeer JW, Kyngdon J (1983) Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 9:31–34

    PubMed  CAS  Google Scholar 

  26. 26.

    Pain JA, Wickremesinghe SS, Bradbeer JW (1990) Combined tamoxifen and anabolic steroid as primary treatment for breast carcinoma in the elderly. Eur J Surg Oncol 16:225–228

    PubMed  CAS  Google Scholar 

  27. 27.

    Allan SG, Rodger A, Smyth JF et al (1985) Tamoxifen as primary treatment of breast cancer in elderly or frail pts: a practical management. Br Med J 290:358

    Article  CAS  Google Scholar 

  28. 28.

    Akhtar SS, Allan SG, Rodger A et al (1991) A 10-year experience of tamoxifen as primary treatment of breast cancer in 100 elderly and frail pts. Eur J Surg Oncol 17:30–35

    PubMed  CAS  Google Scholar 

  29. 29.

    Margolese RG, Foster RS Jr (1989) Tamoxifen as an alternative to surgical resection for selected geriatric pts with primary breast cancer. Arch Surg 124:548–550

    PubMed  CAS  Google Scholar 

  30. 30.

    Falk GL, Gwynne-Jones D, Gray JG (1989) Efficacy of tamoxifen as the primary treatment of operable breast cancer in the high risk pts. Aust N Z J Surg 59:543–545

    PubMed  Article  CAS  Google Scholar 

  31. 31.

    Robertson JF, Ellis IO, Elston CW et al (1992) Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly pts: 5-year follow-up. Eur J Cancer 28A:908–910

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Robertson JF, Todd JH, Ellis IO et al (1998) Comparison of mastectomy with tamoxifen for treating elderly pts with operable breast cancer. BMJ 297:511–514

    Article  Google Scholar 

  33. 33.

    Gazet JC, Markopoulos C, Ford HT et al (1998) Prospective randomized trial of tamoxifen versus surgery in elderly pts with breast cancer. Lancet 1:679–681

    Google Scholar 

  34. 34.

    Bates T, Riley DL, Houghton J et al (1991) Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party. Br J Surg 78:591–594

    PubMed  Article  CAS  Google Scholar 

  35. 35.

    Kenny F, Robertson J, Ellis I et al (1998) Long-term follow-up of elderly pts randomised to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 7:335

    Article  Google Scholar 

  36. 36.

    Mustacchi G, Milani S, Pluchinotta A et al (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly pts with operable breast cancer: the G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res 14:2197–2200

    PubMed  CAS  Google Scholar 

  37. 37.

    Syed B, Johnston S, Wong D et al (2009) Surgery versus primary endocrine therapy for elderly women with ER-positive early operable primary breast cancer: survival analysis and correlation with oER positivity. J Clin Oncol 15(suppl; abstr 612)

  38. 38.

    Brodie AM, Garrett WM, Hendrickson JR et al (1981) Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3, 17-dione and 4-acetoxy-4-androstene-3, 17-dione and sustained effects in vivo. Steroids 38:693–702

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Miller WR, Dixon JM (2002) Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 9:9–15

    PubMed  Google Scholar 

  40. 40.

    Tubiana-Hulin M, Spyratos F, Becette V et al (2003) Phase II study of neo-adjuvant exemestane in postmenopausal pts with operable breast cancer. In: 26th Annual San Antonio breast cancer symposium

  41. 41.

    Semiglazov V, Kletzel A, Zhiltzova V et al (2005) Exemestane vs tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). Proc Am Soc Clin Oncol 25:23530

    Google Scholar 

  42. 42.

    Freedman OC, Amir E, Dranitsaris G et al (2009) A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) AIs on biomarkers in post-menopausal women with hormone receptor positive locally advance. Eur J Cancer 2:269

    Google Scholar 

  43. 43.

    Takei H, Suemasu K, Inoue K et al (2008) Multicenter phase II trial of neoadjuvant exemestane for postmenopausal pts with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 107:87–94

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Mustacchi G, Mansutti M, Sacco C et al (2009) Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Ann Oncol 20:655–659

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Alba E, Calvo L, Albanell J et al (2010) Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: a multicenter, randomized phase II studies (GEICAM/2006-03). J Clin Oncol 28:500

    Google Scholar 

  46. 46.

    Hojo T, Kinoshita T, Wada N et al (2010) Neo-adjuvant exemestane in post menopausal estrogen and/or PR positive breast cancer: a randomized phase II trial to investigate optimal duration (4 month versus 6 month) of preoperative endocrine therapy (PTEX46 trial). In: 33rd Annual San Antonio breast cancer symposium

  47. 47.

    Dixon JM, Renshaw L, Bellamy C et al (2000) The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double blind, single-center study. Clin Cancer Res 6:2229–2235

    PubMed  CAS  Google Scholar 

  48. 48.

    Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Cataliotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer 106:2095–2103

    PubMed  Article  CAS  Google Scholar 

  51. 51.

    Semiglazov VF, Semiglazov VV, Ivanov V et al (2004) The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER positive breast cancer. J Clin Oncol 22:519

    Google Scholar 

  52. 52.

    Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer pts with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1533

    PubMed  Article  CAS  Google Scholar 

  53. 53.

    Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, ER-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816

    PubMed  CAS  Google Scholar 

  54. 54.

    Sinha D, Bahadur AK, Singh K et al (2009) Comparison of neoadjuvant paclitaxel and carboplatin with neoadjuvant letrozole in postmenopausal pts with receptor-positive locally advanced breast cancer (LABC). J Clin Oncol 27:608

    Google Scholar 

  55. 55.

    Baselga J, Semiglazov V, Van Dam P et al (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in pts with ER-positive breast cancer. J Clin Oncol 27:2630–2637

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Forero A, Saleh M, Galleshaw J et al (2010) Long term follow-up of a pilot trial of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or PR positive breast cancer. In: The 33rd Annual San Antonio breast cancer symposium

  57. 57.

    Ellis M, Suman V, Hoog J et al (2010) ACOSOG Z1031. A randomized neoadjuvant comparison between letrozole (LET), anastrozole (ANA) and exemestane (EXE) for postmenopausal women with ER rich stage 2/3 breast cancer: biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype. In: 33rd Annual San Antonio breast cancer symposium

  58. 58.

    Shimizu D, Ishikawa T, Yamada A et al (2010) Preoperative endocrine therapy with tamoxifen and goserelin acetate for hormone receptor-positive premenopausal patients. In: 33rd Annual San Antonio breast cancer symposium

  59. 59.

    Sagara Y, Masuda N, Kinoshita T et al (2010) The STAGE Study. A Phase III Comparison of Anastrozole Plus Goserelin with Tamoxifen Plus Goserelin as Pre-Operative Treatments in Premenopausal Breast Cancer Patients. In: 33rd Annual San Antonio breast cancer symposium

  60. 60.

    Machiavelli MR, Romero AO, Pérez JE et al (1998) Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125–131

    PubMed  CAS  Google Scholar 

  61. 61.

    Dowsett M, Smith IE, Ebbs SR et al (2005) Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 11:951–958

    Google Scholar 

  62. 62.

    Chen AM, Meric-Bernstam F, Hunt KK et al (2005) Breast conservation after neoadjuvant chemotherapy. Cancer 103:689–695

    PubMed  Article  Google Scholar 

  63. 63.

    Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277

    PubMed  Article  Google Scholar 

  64. 64.

    Robertson JF, Come SE, Jones SE et al (2005) Endocrine treatment options for advanced breast cancer—the role of fulvestrant. Eur J Cancer 41:346–356

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Robertson JF (2001) ICI 182,780 (Fulvestrant)—the first oestrogen receptor down-regulator—current clinical data. Br J Cancer 85:11–14

    PubMed  CAS  Google Scholar 

  66. 66.

    Johnston SR, Martin LA, Dowsett M (2005) Life following aromatase inhibitors—where now for endocrine sequencing? Breast Cancer Res Treat 9:19–25

    Article  Google Scholar 

Download references

Conflict of interest

No conflict of interest declared.

Author information



Corresponding author

Correspondence to José Pablo Leone.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Iturbe, J., Leone, J.P., Zwenger, A. et al. Neoadjuvant endocrine treatment of women with breast cancer. Oncol Rev 5, 157 (2011).

Download citation


  • Breast cancer
  • Neoadjuvant therapy
  • Hormone therapy
  • Tamoxifen
  • Aromatase inhibitors